
1. Malar J. 2016 Nov 8;15(1):540.

Plasmodium vivax multidrug resistance-1 gene polymorphism in French Guiana.

Faway E(1)(2), Musset L(1)(3)(4), Pelleau S(1)(3)(4), Volney B(1)(3)(4), Casteras
J(1)(3), Caro V(5), Menard D(6)(7), Briolant S(1)(8)(9), Legrand
E(10)(11)(12)(13)(14).

Author information: 
(1)Laboratoire de Parasitologie, Institut Pasteur de la Guyane, Cayenne, French
Guiana.
(2)URPhyM-NARILIS, University of Namur, Namur, Belgium.
(3)National Reference Center for Malaria, Institut Pasteur de la Guyane, Cayenne,
French Guiana.
(4)World Health Organization Collaborating Center for Surveillance of
Antimalarial Drug Resistance, Institut Pasteur de la Guyane, Cayenne, French
Guiana.
(5)Environment and Infectious Risks unit, Genotyping of Pathogens Pole, Institut 
Pasteur, Paris, France.
(6)Malaria Molecular Epidemiology Unit, Institut Pasteur in Cambodia, Phnom Penh,
Cambodia.
(7)Malaria Translational Research Unit, Institut Pasteur in Cambodia, Phnom Penh,
Cambodia.
(8)Direction Interarmées du Service de Santé, Cayenne, French Guiana.
(9)Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France.
(10)Laboratoire de Parasitologie, Institut Pasteur de la Guyane, Cayenne, French 
Guiana. eric.legrand@pasteur.fr.
(11)National Reference Center for Malaria, Institut Pasteur de la Guyane,
Cayenne, French Guiana. eric.legrand@pasteur.fr.
(12)World Health Organization Collaborating Center for Surveillance of
Antimalarial Drug Resistance, Institut Pasteur de la Guyane, Cayenne, French
Guiana. eric.legrand@pasteur.fr.
(13)Malaria Translational Research Unit, Institut Pasteur, Paris, France.
eric.legrand@pasteur.fr.
(14)Genetics and Genomics of Insect Vectors Unit, Institut Pasteur, Paris,
France. eric.legrand@pasteur.fr.

BACKGROUND: Plasmodium vivax malaria is a major public health problem in French
Guiana. Some cases of resistance to chloroquine, the first-line treatment used
against P. vivax malaria, have been described in the Brazilian Amazon region. The
aim of this study is to investigate a possible dispersion of
chloroquine-resistant P. vivax isolates in French Guiana. The genotype,
polymorphism and copy number variation, of the P. vivax multidrug resistance
gene-1 (pvmdr1) have been previously associated with modification of the
susceptibility to chloroquine.
METHODS: The pvmdr1 gene polymorphism was evaluated by sequencing and copy number
variation was assessed by real-time PCR, in P. vivax isolates obtained from 591
symptomatic patients from 1997 to 2013.
RESULTS: The results reveal that 1.0% [95% CI 0.4-2.2] of French Guiana isolates 
carry the mutations Y976F and F1076L, and that the proportion of isolates with
multiple copies of pvmdr1 has significantly decreased over time, from 71.3%
(OR = 6.2 [95% CI 62.9-78.7], p < 0.0001) in 1997-2004 to 12.8% (OR = 0.03 [95%
CI 9.4-16.9], p < 0.0001) in 2009-2013. A statistically significant relationship 
was found between Guf-A (harboring the single mutation T958M) and Sal-1 (wild
type) alleles and pvmdr1 copy number.
CONCLUSIONS: Few P. vivax isolates harboring chloroquine-resistant mutations in
the pvmdr1 gene are circulating in French Guiana. However, the decrease in the
prevalence of isolates carrying multiple copies of pvmdr1 might indicate that the
P. vivax population in French Guiana is evolving towards a decreased
susceptibility to chloroquine.

DOI: 10.1186/s12936-016-1595-9 
PMCID: PMC5101641
PMID: 27825387  [Indexed for MEDLINE]

